Ischemia-Modified Albumin May be a Novel Marker for the Diagnosis and Follow-up of Necrotizing Enterocolitis

Basit Öğe Kaydı
dc.contributor.authorYakut, Ibrahim
dc.contributor.authorTayman, Cuneyt
dc.contributor.authorOztekin, Osman
dc.contributor.authorNamuslu, Mehmet
dc.contributor.authorKaraca, Fahri
dc.contributor.authorKosus, Aydin
dc.date.accessioned2025-10-24T18:08:47Z
dc.date.available2025-10-24T18:08:47Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractAim We investigate the efficacy of serial ischemia-modified albumin (IMA) measurements in diagnosis and follow-up of necrotizing enterocolitis (NEC), and compare its effectiveness with C-reactive protein (CRP), interleukin-6 (IL-6), in NEC. Methods Preterm infants, whose gestational age and weight matched each other, were grouped as control (n = 36) and NEC (n = 37). IMA, CRP, IL-6 levels were measured on the third day of life for the control group and on the day of diagnosis (first day), third, and seventh days of NEC. Results IMA, CRP, and IL-6 levels were significantly increased in NEC patients compared to the control group (P < 0.001) on the follow-up. IMA levels were significantly higher in infants with stage-III NEC than those in infants with stage-II NEC on the first, third, and seventh days (P < 0.001). The area under curve for IMA (0.815 at diagnosis, 0.933 at the third day, 0.935 at the seventh day) were significantly higher than CRP and IL-6 at all days for predicting perforation in infants with NEC (P < 0.001). Similarly, the area under curve for IMA (0.952 at diagnosis, 0.929 at the third day, 0.971 at the seventh day) was significantly higher than CRP and IL-6 at all consequent days of diagnosis for predicting mortality in infants with NEC (P < 0.001). Conclusion Ischemia-modified albumin was found to be superior to CRP and IL-6 in both diagnosis and follow-up of NEC.
dc.identifier.doi10.1002/jcla.21661
dc.identifier.endpage177
dc.identifier.issn0887-8013
dc.identifier.issn1098-2825
dc.identifier.issue3
dc.identifier.pmid24395148
dc.identifier.scopus2-s2.0-84899620358
dc.identifier.scopusqualityQ1
dc.identifier.startpage170
dc.identifier.urihttps://doi.org/10.1002/jcla.21661
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3285
dc.identifier.volume28
dc.identifier.wosWOS:000335398600002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal Of Clinical Laboratory Analysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectnewborn; ischemia-modified albumin; necrotizing enterocolitis; preterm; diagnosis
dc.titleIschemia-Modified Albumin May be a Novel Marker for the Diagnosis and Follow-up of Necrotizing Enterocolitis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu